Obesity increases the risk of numerous secondary diseases such as type 2 diabetes, high blood pressure and mental illness. Prof. Dr. Kerstin Stemmer, Professor of Molecular Cell Biology at the ...

The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

In fact, you may have gotten more than a few targeted ads on social media from telehealth platforms selling these cheaper GLP ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...